SB 408 Maryland Department of Health Reports on Standing Orders and Opioid Overdose Reversal Drugs

About SB-408

Requiring the Maryland Department of Health to report, on or before December 1, 2024, December 1, 2025, and December 1, 2026, to the Senate Finance Committee and the House Health and Government Operations Committee on current opioid overdose reversal drugs approved by the federal Food and Drug Administration and, for any approved opioid overdose reversal drug, whether the Department has added the drug to a standing order and, if not, the reasons why the drug has not been added.